UM  > 中華醫藥研究院
Oral delivery of a nanocrystal formulation of schisantherin a with improved bioavailability and brain delivery for the treatment of Parkinson's disease
Chen T.2; Li C.2; Li Y.2; Yi X.1; Lee S.M.-Y.2; Zheng Y.2
2016-11-07
Source PublicationMolecular Pharmaceutics
ISSN15438392 15438384
Volume13Issue:11Pages:3864-3875
Abstract

Schisantherin A (SA) is a promising anti-Parkinsonism Chinese herbal medicine but with poor water solubility and challenges to be delivered to the brain. We formulated SA as nanocrystals (SA-NC), aiming to improve its solubility and pharmacokinetic profile and thus provide a potential therapeutic agent for the treatment of Parkinson's disease (PD). The rod-shaped SA-NC had a particle size of ∼160 nm with 33.3% drug loading, and the nanocrystals exhibited a fast dissolution rate in vitro. The intact drug nanocrystals could be internalized into Madin-Darby canine kidney (MDCK) cells, which were followed by rapid intracellular release, and most of the drug was transported to the basolateral side in its soluble form. Following oral administration of the SA-NC or an SA suspension, the accumulated concentration of the SA-NC in the plasma and brain was considerably higher than that observed for the SA suspension, but the drug targeting efficiency was similar. The SA-NC significantly reversed the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic (DA) neuronal loss and locomotion deficiency in zebrafish, as well as the 1-methyl-4-phenylpyridinium ion (MPP)-induced damage of neuronal cell culture model. Further Western blot analysis demonstrated that the stronger neuroprotective effect of SA-NC may be partially mediated by the activation of the protein kinase B (Akt)/glycogen synthase kinase-3β (Gsk3β) pathway. Taken together, these data provide solid evidence that the nanocrystal formulation has the potential to improve the bioavailability and brain concentration of this Biopharmaceutics Classification System (BCS) class II compound, SA, for the treatment of PD.

KeywordBrain Delivery Dissolution Nanocrystals Oral Bioavailability Parkinson's Disease (Pd)
DOI10.1021/acs.molpharmaceut.6b00644
URLView the original
Indexed BySCI
WOS Research AreaResearch & Experimental Medicine ; Pharmacology & Pharmacy
WOS SubjectMedicine, Research & Experimental ; Pharmacology & Pharmacy
WOS IDWOS:000387428300026
Fulltext Access
Citation statistics
Cited Times [WOS]:12   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Affiliation1.The University of North Carolina at Chapel Hill
2.University of Macau
First Author AffilicationUniversity of Macau
Recommended Citation
GB/T 7714
Chen T.,Li C.,Li Y.,et al. Oral delivery of a nanocrystal formulation of schisantherin a with improved bioavailability and brain delivery for the treatment of Parkinson's disease[J]. Molecular Pharmaceutics,2016,13(11):3864-3875.
APA Chen T.,Li C.,Li Y.,Yi X.,Lee S.M.-Y.,&Zheng Y..(2016).Oral delivery of a nanocrystal formulation of schisantherin a with improved bioavailability and brain delivery for the treatment of Parkinson's disease.Molecular Pharmaceutics,13(11),3864-3875.
MLA Chen T.,et al."Oral delivery of a nanocrystal formulation of schisantherin a with improved bioavailability and brain delivery for the treatment of Parkinson's disease".Molecular Pharmaceutics 13.11(2016):3864-3875.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Chen T.]'s Articles
[Li C.]'s Articles
[Li Y.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Chen T.]'s Articles
[Li C.]'s Articles
[Li Y.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Chen T.]'s Articles
[Li C.]'s Articles
[Li Y.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.